Adaptimmune Therapeutics plc (473A) — Strategic Asset Allocation Index
Adaptimmune Therapeutics plc (473A) has a Strategic Asset Allocation Index of 61.2% as of June 2023. Strategic assets (PP&E of €77.52 Million plus long-term investments of €-) total €77.52 Million, measured against net assets of €126.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Adaptimmune Therapeutics plc Strategic Asset Allocation Index (2016–2022)
This chart shows how Adaptimmune Therapeutics plc's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 61.2%, representing strategic assets of €77.52 Million against net assets of €126.65 Million EUR. Explore cash efficiency ratio of Adaptimmune Therapeutics plc to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Adaptimmune Therapeutics plc (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Adaptimmune Therapeutics plc from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Adaptimmune Therapeutics plc.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 87.4% | €71.53 Million | €71.53 Million | €- | €81.88 Million | ▲ +62.4 pp |
| 2021 | 24.9% | €51.37 Million | €51.37 Million | €- | €205.96 Million | ▲ +11.3 pp |
| 2020 | 13.7% | €46.66 Million | €46.66 Million | €- | €341.23 Million | ▼ -28.3 pp |
| 2019 | 41.9% | €51.86 Million | €51.86 Million | €- | €123.64 Million | ▲ +27.3 pp |
| 2018 | 14.6% | €36.12 Million | €36.12 Million | €- | €246.88 Million | ▼ -5.4 pp |
| 2017 | 20.0% | €40.68 Million | €40.68 Million | €- | €202.98 Million | ▲ +3.2 pp |
| 2016 | 16.8% | €27.90 Million | €27.90 Million | €- | €166.14 Million | — |